

Regeneron is a leading biotechnology company that invents, develops, manufactures and commercializes life-transforming medicines for people with serious diseases.

Our innovative culture pushes the bounds of science to make life-changing medicines

LEADING TECHNOLOGY

We accelerate drug development using proprietary technologies, such as *VelociSuite*®, and are pioneering genetic medicine platforms, enabling us to identify innovative targets and complementary approaches to potentially treat or cure diseases.

DRIVEN BY DISCOVERY

We tap into our growing database of millions of sequenced exomes using proprietary data analytics, technology and human ingenuity to make meaningful and promising biological discoveries at speed and scale.

BROAD PIPELINE

Our pipeline is powered by end-to-end research and development capabilities, and designed to help patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, neurological diseases, hematologic conditions, infectious diseases, and rare diseases.

MEDICINES

Our unique ability to repeatedly and consistently translate science into medicine has led to numerous approved treatments, with Regeneron-invented medicines available in over 100 countries.

Our Leadership



Leonard S. Schleifer, M.D., Ph.D.

Board co-Chair, President and Chief Executive Officer



George D. Yancopoulos, M.D., Ph.D.

Board co-Chair, President and Chief Scientific Officer

BOARD OF DIRECTORS

- Six of our 13 directors are members of the National Academy of Sciences
- Board includes two Nobel laureates and holders of many scientific awards
- Substantial governance, financial, policy and management expertise



Regeneron By The Numbers



OUR SCIENCE & MEDICINES

- **15 medicines** approved or authorized
- **Nearly 50 product candidates** in clinical development
- **50+ countries** with clinical trials
- **3M+ exomes sequenced** by the Regeneron Genetics Center®



OUR COMPANY

- **35+ years** of scientific leadership
- **15.4K+ Regeneron employees** across North America, Europe and Asia
- **Top 5 Ranking** in *Science* magazine's global Top Employer survey for 14 consecutive years
- **\$5.9B invested in R&D** in 2025



OUR RESPONSIBILITY

- **Top 10%** ranking in biotech industry across 3 leading ESG ratings
- **4M+ students** reached by Regeneron STEM initiatives since 2020
- **50%** employee volunteerism rate in 2025 – twice the global average
- **Up to 500 doses** of our Ebola medicine donated to the World Health Organization for use in countries most at-risk